Clinical Trial Update: Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating OXERVATE (cenegermin) for stage 1 neurotrophic keratitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurotrophic Keratitis

Drugs mentioned

• Oxervate (cenegermin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Neurotrophic Keratitis | Phase 4 | Status: COMPLETED | Results posted: 2023-06-23